Human Reproduction, Vol. 14, No. 6, 1426-1430,
June 1999
© 1999 European Society of Human Reproduction and Embryology
Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles
1 Center for Reproductive Medicine, University Hospital and Medical School, Dutch-speaking Brussels Free University, Laarbeeklaan 101, 1090 Brussels, Belgium and 2 ASTA Medica AG, Frankfurt Main, Germany
The luteal phase hormonal profile and the clinical outcome of 69 patients undergoing in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) after ovarian stimulation with human menopausal gonadotrophin (HMG) and the gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix were analysed. Twenty-four patients received Cetrorelix 0.5 mg (group I) while in 45 patients Cetrorelix 0.25 mg was administered (group II). Human chorionic gonadotrophin (HCG) was used as luteal support. Nine clinical pregnancies were obtained in group I (37.5%) and 12 in group II (26.6%). These results were not significantly different. Serum progesterone and oestradiol concentrations did not differ between the two groups either in pregnant or non-pregnant patients. An expected decrease of the same hormones was observed 8 days after the pre-ovulatory HCG injection in non-pregnant women. With regard to serum luteinizing hormone concentrations, a decrease was observed 2 days after the pre-ovulatory HCG injection and was maintained at almost undetectable levels throughout the entire luteal phase in both conception and non-conception cycles of group I and group II. This study demonstrates that different doses of GnRH antagonist do not have any impact on the luteal phase of IVF/ICSI cycles when hormonal support is given.
Key words: GnRH antagonist/ICSI/IVF/luteal phase
3 To whom correspondence should be addressed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H.M. Fatemi, C. Bourgain, P. Donoso, C. Blockeel, E.G. Papanikolaou, B. Popovic-Todorovic, and P. Devroey Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: a proof of concept Hum. Reprod., May 1, 2007; 22(5): 1260 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.G. Crosignani, E. Somigliana, and on behalf of the Intrauterine Insemination (IUI) S Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial Hum. Reprod., February 1, 2007; 22(2): 500 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Vlahos, C. W. Lipari, B. Bankowski, T.-H. Lai, J. A. King, I.-M. Shih, K. Fragakis, and Y. Zhao Effect of Luteal-Phase Support on Endometrial L-Selectin Ligand Expression after Recombinant Follicle-Stimulating Hormone and Ganirelix Acetate for in Vitro Fertilization J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4043 - 4049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pirard, J. Donnez, and E. Loumaye GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study Hum. Reprod., July 1, 2006; 21(7): 1894 - 1900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pirard, J. Donnez, and E. Loumaye GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin Hum. Reprod., July 1, 2005; 20(7): 1798 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. M. Beckers, N. S. Macklon, M. J. Eijkemans, M. Ludwig, R. E. Felberbaum, K. Diedrich, S. Bustion, E. Loumaye, and B. C. J. M. Fauser Nonsupplemented Luteal Phase Characteristics after the Administration of Recombinant Human Chorionic Gonadotropin, Recombinant Luteinizing Hormone, or Gonadotropin-Releasing Hormone (GnRH) Agonist to Induce Final Oocyte Maturation in in Vitro Fertilization Patients after Ovarian Stimulation with Recombinant Follicle-Stimulating Hormone and GnRH Antagonist Cotreatment J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4186 - 4192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. V. Nagaraja, B. Pechstein, K. Erb, C. Klipping, R. Hermann, M. Locher, and H. Derendorf Pharmacokinetic/Pharmacodynamic Modeling of Luteinizing Hormone (LH) Suppression and LH Surge Delay by Cetrorelix after Single and Multiple Doses in Healthy Premenopausal Women J. Clin. Pharmacol., March 1, 2003; 43(3): 243 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ragni, W. Vegetti, E. Baroni, M. Colombo, M. Arnoldi, G. Lombroso, and P. G. Crosignani Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist Hum. Reprod., November 1, 2001; 16(11): 2258 - 2262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tavaniotou, C. Albano, J. Smitz, and P. Devroey Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix Hum. Reprod., April 1, 2001; 16(4): 663 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The European Orgalutran Study Group, G. Borm, and B. Mannaerts Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial Hum. Reprod., July 1, 2000; 15(7): 1490 - 1498. [Abstract] [Full Text] [PDF]
|
|